CorMedix Confirms Nasdaq Listing for Common Stock
Ticker: CRMD · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1410098
| Field | Detail |
|---|---|
| Company | Cormedix Inc. (CRMD) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, exchange-listing
TL;DR
**CorMedix just filed an 8-K confirming its common stock is still listed on Nasdaq under CRMD.**
AI Summary
CorMedix Inc. filed an 8-K on January 30, 2024, to update its registration information, specifically confirming its common stock, with a $0.001 par value, is registered on the Nasdaq Global Market under the trading symbol CRMD. This filing primarily serves to ensure compliance with SEC regulations regarding publicly traded securities. For investors, this matters because it reaffirms the company's continued listing and trading on a major exchange, providing liquidity and visibility for their shares.
Why It Matters
This filing confirms CorMedix's compliance with SEC regulations and its continued listing on the Nasdaq Global Market, which is crucial for investor confidence and stock liquidity.
Risk Assessment
Risk Level: low — This filing is a routine administrative update and does not indicate any new financial or operational risks for the company.
Analyst Insight
This filing is a routine compliance update and does not present new information that would warrant immediate buying or selling action. Investors should continue to monitor CorMedix's financial performance and product development for substantive news.
Key Numbers
- $0.001 — par value per share (the stated par value of CorMedix's common stock)
Key Players & Entities
- CorMedix Inc. (company) — the registrant filing the 8-K
- Nasdaq Global Market (company) — the exchange where CorMedix's common stock is registered
- CRMD (other) — the trading symbol for CorMedix's common stock
- $0.001 (dollar_amount) — the par value of CorMedix's common stock
- January 30, 2024 (date) — the date of the earliest event reported in the 8-K
Forward-Looking Statements
- CorMedix Inc. will maintain its listing on the Nasdaq Global Market. (CorMedix Inc.) — high confidence, target: 2025-01-30
FAQ
What is the primary purpose of this 8-K filing by CorMedix Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits,' specifically confirming that CorMedix Inc.'s common stock, with a $0.001 par value, is registered pursuant to Section 12(b) of the Exchange Act and listed on the Nasdaq Global Market under the trading symbol CRMD, as of January 30, 2024.
On which exchange is CorMedix Inc.'s common stock registered?
CorMedix Inc.'s common stock is registered on the Nasdaq Global Market, as stated in the 'Securities registered pursuant to Section 12(b) of the Exchange Act' section of the filing.
What is the trading symbol for CorMedix Inc.'s common stock?
The trading symbol for CorMedix Inc.'s common stock is CRMD, as indicated in the 'Title of each class' table within the filing.
What is the par value of CorMedix Inc.'s common stock?
The par value of CorMedix Inc.'s common stock is $0.001, as specified in the 'Title of each class' table in the filing.
What was the 'Date of earliest event reported' for this 8-K filing?
The 'Date of Report (Date of earliest event reported)' for this 8-K filing was January 30, 2024.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-01-30 17:26:20
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CRMD Nasdaq Global Market
Filing Documents
- ea192430-8k_cormedix.htm (8-K) — 24KB
- ea192430ex99-1_cormedix.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 18KB
- 0001213900-24-008015.txt ( ) — 235KB
- crmd-20240130.xsd (EX-101.SCH) — 3KB
- crmd-20240130_lab.xml (EX-101.LAB) — 33KB
- crmd-20240130_pre.xml (EX-101.PRE) — 22KB
- ea192430-8k_cormedix_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On January 30, 2024, CorMedix Inc. (the "Company") issued a press release announcing updates related to its business and anticipated launch of DefenCath, including that it received a benefit determination from the Center for Medicare & Medicaid Services as described in the attached release. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORMEDIX INC. Date: January 30, 2024 By: /s/ Joseph Todisco Name: Joseph Todisco Title: Chief Executive Officer 2